通心络胶囊联合津力达颗粒对2型糖尿病患者血糖及血管内皮功能的影响

The effect of Tongxinluo capsule combined with Jinlida sintervention on vascular endothelial fuction and blood glucose in the patients with Type 2 diabetes

目的探讨通心络胶囊联合津力达颗粒对2型糖尿病（type2diabetes，T2DM）患者血糖及血管内皮功能的影响。方法将100例T2DM患者按随机数字表法分为2组各50例，2组患者均皮下注射门冬胰岛素30注射液、口服辛伐他汀降脂及肠溶阿司匹林抗血小板聚集，观察组在对照组基础上加服通心络胶囊及津力达颗粒。均治疗12周。采用双抗体两步夹心ELISA测定血管内皮生长因子（vascularendothelialgrowthfactor,VEGF），采用放射免疫分析法测定内皮素．1（endothelin．1，ET-1），采用硝酸还原酶法测定NO，采用美国AU5800系列全自动生化分析仪测定血糖及HbAlc，并对结果进行比较。结果治疗后，观察组FPG[（7．03±2．11）mmol／L比（8．09±2．03）mmol／L，t=1．911]、2hPG[（9．27±2．03）mmol／L比（12．06±3．54）mmol／L，f=1．946]、HbAlc[（6．98±1．58）％比（8．06±2．13）％，t=2．013]水平均低于对照组（P〈0．05）。与对照组治疗后比较，观察组VEGF[（684．61±84．37）ng／L比（514．28±79．52）ng／L，t=2．136]、NO[（43．28±6．40）ng／L比（34．64±6．70）ngm，t=2．097]水平升高（P〈0．05），ET-1[（53．13±7．24）gmol/L比（60．09±7．18）gmol／L，t=2．271]下降（P〈0．05）。结论通心络胶囊联合联合津力达颗粒可降低T2DM患者血糖水平，改善血管内皮功能。

Objective To observe the effect of Tongxinluo capsule combined with Jinlidas intervention on vascular endothelial fuction and blood glucose in the patients with Type 2 diabetes. Methods A total of 100 patients with Type 2 diabetes were randomly divided into treatment and control groups with 50 patients each. Both groups were received subcutaneous injection insulin, oral admistration of Simvastatin and Aspirin. And the treatment group were received Tongxinluo capsule and Jinlida sintervention based on the standard treatment. The changes of serum levels ofFPG, 2hPG, HbAlc, VEGF, NO, ET-1 were observed before and after treatement. All the patients were treated for 12 weeks. Results After the treatment, the serum of FPG （7.03 ± 2.11 mmol/L vs. 8.09± 2.03 mmol/L, t=1.911）, 2hPG （9.27 ± 2.03 mmol/L vs. 12.06 ± 3.54 mmol/L, t=-1.946）, HbAlc （6.98% ± 1.58% vs. 8.06% ± 2.13%, t=-2.013） were decreasd （P〈0.05）. Besides, VEGF （684.61 ± 84.37 ng/L vs. 514.28 ± 79.52 ng/L, t=2.136）, NO （43.28 ± 6.40 ng/L vs. 34.64 ± 6.70 ng/L, t=2.097） of treatment group were siginificantly higher than the control group （P〈0.05）, while ET-1 （53.13 ± 7.24 μmol/L vs. 60.09 ± 7.18 μmol/L, r=2.271） were siginificantly lower （P〈0.05）. Conclusion Tongxinluo capsule combined with Jinlida sintervention could decreased the level Blood glucose and improve vascular endothelial ruction in the patients with Type 2 diabetes.